{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:49:33Z","timestamp":1794199773944,"version":"4.8.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Postural Orthostatic Tachycardia Syndrome (POTS) is a complex form of dysautonomia that presents with abnormal autonomic reflexes upon standing, leading to symptoms such as lightheadedness, tachycardia, fatigue, and cognitive impairment. The COVID-19 pandemic has brought renewed attention to POTS due to its overlap with post-acute sequelae of COVID-19 (PASC). Studies have found that a substantial percentage of COVID-19 survivors exhibit symptoms resembling POTS, elevating POTS diagnoses to previously unseen levels. We systematically reviewed the literature for existing high-quality evidence on potential interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of the literature was performed to identify studies of oral medications for the management of POTS. We searched for published manuscripts on the medical management of POTS through 6 April 2024 which met pre-specified inclusion criteria. We conducted quality appraisal and assessed risk of bias before extracting the data and performing synthesis to determine the current state of the evidence; particularly in the context of PASC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study search and selection process identified 32 studies that met inclusion criteria, comprising randomized controlled trials, observational studies, and systematic reviews. Most included studies were judged to be of moderate to high quality, with largely low risk of bias. The most frequently studied medications were beta-blockers, ivabradine, and midodrine. Ivabradine and midodrine demonstrated the highest rate of symptomatic improvement, while beta-blockers showed the largest reduction in heart rate variability. Limited evidence was available for PASC-associated POTS, but findings suggest that treatments may have similar efficacy in both PASC and non-PASC cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ivabradine, midodrine, and beta-blockers currently appear to be reasonable front-line choices in pharmacologic management of POTS (PASC associated and otherwise). Further RCTs that evaluate long term outcomes of medications are needed to further establish evidence based pharmacologic treatment approaches for POTS. Particular areas of inquiry include differential efficacy of recommended therapies based on POTS subtypes, and a need for treatments directly targeting the underlying autonomic nervous system dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      PROSPERO, identifier CRD42024505967,\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=505967<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2024.1515486","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T04:26:06Z","timestamp":1736915166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic"],"prefix":"10.3389","volume":"15","author":[{"given":"Benjamin C.","family":"Pierson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Apilado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alaric","family":"Franzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tribble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey Perez","family":"Koehlmoos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jacc.2018.11.059","article-title":"Postural orthostatic tachycardia syndrome","volume":"73","author":"Bryarly","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.14503\/THIJ-19-7060","article-title":"Postural orthostatic tachycardia syndrome","volume":"47","author":"Safavi-Naeini","year":"2020","journal-title":"Tex Heart Inst J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.15585\/mmwr.mm7232a3","article-title":"Long COVID and significant activity limitation among adults, by age \u2014 United States, June 1\u201313, 2022, to June 7\u201319, 2023","volume":"72","author":"Ford","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/joim.13245","article-title":"Postural orthostatic tachycardia syndrome is associated with significant employment and economic loss","volume":"290","author":"Bourne","year":"2021","journal-title":"J Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s40265-018-0931-5","article-title":"Postural orthostatic tachycardia syndrome: prevalence, pathophysiology, and management","volume":"78","author":"Zadourian","year":"2018","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/13543784.2022.2121697","article-title":"Postural orthostatic tachycardia syndrome: pathophysiology, management, and experimental therapies","volume":"31","author":"Narasimhan","year":"2022","journal-title":"Expert Opin Investig Drugs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/joim.12852","article-title":"Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management","volume":"285","author":"Fedorowski","year":"2019","journal-title":"J Intern Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.hrthm.2015.03.029","article-title":"2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope","volume":"12","author":"Sheldon","year":"2015","journal-title":"Heart Rhythm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1177\/0009922816638663","article-title":"Improvement in functioning and psychological distress in adolescents with postural orthostatic tachycardia syndrome following interdisciplinary treatment","volume":"55","author":"Bruce","year":"2016","journal-title":"Clin Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102836","DOI":"10.1016\/j.autneu.2021.102836","article-title":"Postural orthostatic tachycardia syndrome (POTS): priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting \u2013 Part 2","volume":"235","author":"Raj","year":"2021","journal-title":"Auton Neurosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","article-title":"Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review","volume":"226","author":"Chen","year":"2022","journal-title":"J Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S0002934323004023","DOI":"10.1016\/j.amjmed.2023.06.010","article-title":"High incidence of autonomic dysfunction and postural orthostatic tachycardia syndrome in patients with long COVID: implications for management and health care planning","volume":"2023","author":"Seeley","year":"2023","journal-title":"Am J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41569-023-00842-w","article-title":"Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome","volume":"20","author":"Fedorowski","year":"2023","journal-title":"Nat Rev Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10286-021-00798-2","article-title":"Long-COVID postural tachycardia syndrome: an American Autonomic Society statement","volume":"31","author":"Raj","year":"2021","journal-title":"Clin Auton Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid Synth"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11124","DOI":"10.11124\/JBIES-24-00103","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for cohort studies","volume":"10","author":"Barker","year":"2024","journal-title":"JBI Evid Synth."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2019","journal-title":"JBI Database Syst Rev Implement Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int J Evid Based Healthc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods."},{"key":"B20","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"2019","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1540-8159.2008.02207.x","article-title":"Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and \u03b2-blockers","volume":"32","author":"Lai","year":"2009","journal-title":"PACE-Pacing Clin Electrophysiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jgf2.670","article-title":"Treatment of long COVID complicated by postural orthostatic tachycardia syndrome-Case series research","volume":"25","author":"Tsuchida","year":"2024","journal-title":"J Gen Fam Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF02281112","article-title":"Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone","volume":"10","author":"Freitas","year":"2000","journal-title":"Clin Auton Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"930994","DOI":"10.3389\/fcvm.2022.930994","article-title":"Baroreflex sensitivity predicts therapeutic effects of metoprolol on pediatric postural orthostatic tachycardia syndrome","volume":"9","author":"Cui","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/CM9.0000000000001698","article-title":"Baseline left ventricular ejection fraction associated with symptom improvements in both children and adolescents with postural tachycardia syndrome under metoprolol therapy","volume":"134","author":"Wang","year":"2021","journal-title":"Chin Med J Engl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0121913","DOI":"10.1371\/journal.pone.0121913","article-title":"Plasma C-type natriuretic peptide as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS ONE."},{"key":"B27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.amjcard.2014.05.039","article-title":"Usefulness of plasma copeptin as a biomarker to predict the therapeutic effectiveness of metoprolol for postural tachycardia syndrome in children","volume":"114","author":"Zhao","year":"2014","journal-title":"Am J Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s13311-018-0612-9","article-title":"Efficacy of propranolol, bisoprolol, and pyridostigmine for postural tachycardia syndrome: a randomized clinical trial","volume":"15","author":"Moon","year":"2018","journal-title":"Neurotherapeutics."},{"key":"B29","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1253\/circj.CJ-10-0514","article-title":"Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome","volume":"75","author":"Chen","year":"2011","journal-title":"Circ J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jpeds.2013.04.039","article-title":"Postural orthostatic tachycardia syndrome with increased erythrocytic hydrogen sulfide and response to midodrine hydrochloride","volume":"163","author":"Yang","year":"2013","journal-title":"J Pediatr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1017\/S1047951118001373","article-title":"Utilisation of medications to reduce symptoms in children with postural orthostatic tachycardia syndrome","volume":"28","author":"Boris","year":"2018","journal-title":"Cardiol Young."},{"key":"B32","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.amjcard.2013.05.008","article-title":"Flow-mediated vasodilation as a predictor of therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome","volume":"112","author":"Liao","year":"2013","journal-title":"Am J Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00246-013-0843-9","article-title":"Difference between supine and upright blood pressure associates to the efficacy of midodrine on postural orthostatic tachycardia syndrome (POTS) in children","volume":"35","author":"Deng","year":"2014","journal-title":"Pediatr Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jacc.2012.04.025","article-title":"Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome","volume":"60","author":"Zhang","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1042\/CS20130222","article-title":"double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome","volume":"126","author":"Ross","year":"2014","journal-title":"Clin Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0735-1097(23)00500-4","article-title":"Ivabradine effects on COVID-19-associated postural orthostatic tachycardia syndrome: a single center prospective study","volume":"13","author":"Abdelnabi","year":"2023","journal-title":"Am J Cardiovasc Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1017\/S1047951120001341","article-title":"Ivabradine in children with postural orthostatic tachycardia syndrome: a retrospective study","volume":"30","author":"Towheed","year":"2020","journal-title":"Cardiol Young."},{"key":"B38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40256-017-0248-x","article-title":"Ivabradine in postural orthostatic tachycardia syndrome: preliminary experience in children","volume":"18","author":"Delle Donne","year":"2018","journal-title":"Am J Cardiovasc Drugs."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/pace.13182","article-title":"Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience","volume":"40","author":"Ruzieh","year":"2017","journal-title":"Pacing Clin Electrophysiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/europace\/euq390","article-title":"Single centre experience of ivabradine in postural orthostatic tachycardia syndrome","volume":"13","author":"McDonald","year":"2011","journal-title":"Europace."},{"key":"B41","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacc.2020.12.029","article-title":"Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome","volume":"77","author":"Taub","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.arcped.2020.06.001","article-title":"Short-term efficacy of ORS formulation and propranolol regimen in children with POTS","volume":"27","author":"Yozgat","year":"2020","journal-title":"Arch Pediatr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e38887","DOI":"10.7759\/cureus.38887","article-title":"Choices and challenges with drug therapy in postural orthostatic tachycardia syndrome: a systematic review","volume":"15","author":"Vasavada","year":"2023","journal-title":"Cureus."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1177\/0883073820948679","article-title":"Treatment of postural orthostatic tachycardia syndrome with medication: a systematic review","volume":"35","author":"Hasan","year":"2020","journal-title":"J Child Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40256-017-0252-1","article-title":"Ivabradine for the treatment of postural orthostatic tachycardia syndrome: a systematic review","volume":"18","author":"Gee","year":"2018","journal-title":"Am J Cardiovasc Drugs."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.mayocp.2018.01.025","article-title":"Efficacy of therapies for postural tachycardia syndrome: a systematic review and meta-analysis","volume":"93","author":"Wells","year":"2018","journal-title":"Mayo Clin Proc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fped.2019.00460","article-title":"Efficacy of \u03b2-blockers on postural tachycardia syndrome in children and adolescents: a systematic review and meta-analysis","volume":"7","author":"Deng","year":"2019","journal-title":"Front Pediatr."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/jim-2020-001272","article-title":"Bupropion in the treatment of postural orthostatic tachycardia syndrome (POTS): a single-center experience","volume":"68","author":"Vyas","year":"2020","journal-title":"J Investig Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e43426","DOI":"10.7759\/cureus.43426","article-title":"Low-dose naltrexone use in postural orthostatic tachycardia syndrome: a case series","volume":"15","author":"Stallkamp Tidd","year":"2023","journal-title":"Cureus."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1017\/S1047951118001415","article-title":"Therapy for fatigue and cognitive dysfunction in postural orthostatic tachycardia syndrome","volume":"28","author":"Boris","year":"2018","journal-title":"Cardiol Young."},{"key":"B51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-54165-1_5","article-title":"Pathophysiology and Classification of PoTS","volume-title":"Postural Tachycardia Syndrome","author":"Lloyd","year":"2021"},{"key":"B52","unstructured":""},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2790711\/v1","article-title":"Comparative cohort study of post-acute COVID-19 infection with a nested, randomized controlled trial of ivabradine for those with postural orthostatic tachycardia syndrome (The COVIVA Study)","author":"Saunders","year":"2023","journal-title":"medRxiv."},{"key":"B54","unstructured":"UK\n              P\n            \n          \n          Using technology at home to diagnose and manage POTS-POTS UK\n          \n          2024"},{"key":"B55","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jpeds.2020.05.017","article-title":"Heart rate and heart rate difference predicted the efficacy of metoprolol on postural tachycardia syndrome in children and adolescents","volume":"224","author":"Wang","year":"2020","journal-title":"J Pediatr."},{"key":"B56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/HYPERTENSIONAHA.111.172262","article-title":"Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome","volume":"58","author":"Fu","year":"2011","journal-title":"Hypertension."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1515486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T04:26:15Z","timestamp":1736915175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1515486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":56,"alternative-id":["10.3389\/fneur.2024.1515486"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1515486","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"article-number":"1515486"}}